CLEVELAND--(BUSINESS WIRE)--Medical device and technology company Lazurite has been recognized by MedTech Outlook magazine as a 2022 Top 10 Surgical Solutions Provider for its ArthroFree™ Wireless Camera System for arthroscopy and general endoscopy. MedTech Outlook is a print and digital magazine that bridges the gap between medical technology companies and healthcare providers.
In announcing the 2022 Top 10 Surgical Solutions Providers, the magazine wrote:
“The rising demand for surgical efficiency and precision has led to the increased adoption of automated and sophisticated technologies within hospitals and operating rooms today. The next-generation technologies are contributing to the rise of digital operating rooms that can integrate images, information and workflow to add intelligence to surgical procedures….To help [healthcare providers and surgeons take advantage of these technologies], MedTech Outlook has compiled a list of the top ten surgical device providers.”
Read the article about Lazurite and the ArthroFree™ System.
“We are proud to be included on MedTech Outlook’s list of the Top 10 Surgical Solutions Providers of 2022,” Lazurite CEO and cofounder Eugene Malinskiy said. "The ArthroFree™ System is the first wireless surgical camera system to receive FDA market clearance for arthroscopy and general endoscopy. While there have been incremental advances in surgical camera technology over the years, the ArthroFree System marks the beginning of the era of real-time wireless surgical visualization. With its elimination of the cables inherent to surgical cameras, the ArthroFree System promises ease of use, improved OR efficiency, reduced costs, and better patient outcomes.”
Lazurite (formerly Indago) is a pre-revenue medical device startup company backed by private capital. The company has raised more than $25 million to date from institutional investors, family offices, and more than 70 physician champions. The Cleveland-based company (est. 2015) designs devices to set new operating-room standards for efficiency and patient safety. Lazurite’s ArthroFree™ System is the first wireless surgical camera system to receive FDA market clearance for arthroscopy and general endoscopy. The ArthroFree System ushers in a new era of wireless surgical visualization in minimally invasive surgery. It is designed to meet the needs of surgeons seeking more-nimble, cutting-edge surgical tools. Lazurite’s current product pipeline includes devices that incorporate their patented camera technology and laser light technology. Lazurite’s technologies are protected by a comprehensive intellectual property portfolio encompassing the ArthroFree wireless surgical camera system and the novel Meridiem™ light source as well as other products currently in development. For more information, see: https://lazurite.co.
This press release includes “forward-looking statements." Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “promises,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will,” “designed,” “milestone,” “marks,” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding the expected impact of the ArthroFree System on the field of minimally invasive surgery, and particularly arthroscopic surgery, and our future sales of the ArthroFree System. In addition, the future business impact of being recognized by MedTech Outlook is unknown and not an assurance of future performance. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Lazurite™, ArthroFree™, and Meridiem™ are trademarks of Lazurite Holdings LLC.
Visit lazurite.co/media for videos, logos, images, fact sheets, bios and more.